E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
metastatic non-small-cell lung cancer |
cáncer de pulmón de células no pequeñas metastásico |
|
E.1.1.1 | Medical condition in easily understood language |
metastatic non-small-cell lung cancer |
cáncer de pulmón de células no pequeñas metastásico |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | SOC |
E.1.2 | Classification code | 10029104 |
E.1.2 | Term | Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess 1-year survival rate in patients treated with Tedopi plus docetaxel (arm A) or Tedopi plus nivolumab (arm B) or docetaxel as single agent (arm C) in subjects with advanced NSCLC progressing on first-line chemoimmunotherapy. |
Evaluar la supervivencia global (SG) a un año en pacientes tratados con Tedopi más docetaxel (brazo A) y Tedopi más nivolumab (brazo B) o docetaxel como agente único (brazo C). |
|
E.2.2 | Secondary objectives of the trial |
• To assess Overall Survival (OS) • To assess Progression-free survival (PFS) • To assess Objective Response Rate (ORR) • To assess treatment safety Exploratory • To assess correlation of ORR, PFS and OS with biomarkers in tumor tissue or blood. |
• Evaluación de la SG (OS, por sus siglas en inglés) general. • Evaluación de la supervivencia sin progresión (SSP, o PFS Progression-free survival). • Evaluación de la tasa de respuesta objetiva (TRO, o ORR por sus siglas en inglés). • Evaluación de la seguridad del tratamiento. • Evaluar la correlación entre la TRO, la SSP, la SG y los biomarcadores en sangre y tejido tumoral. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Male and female patients willing and able to give written informed consent; 2. Histological or cytological confirmed diagnosis of HLA-A2+ NSCLC with no evidence of EGFR mutations or ALK or ROS1 rearrangement; 3. Evidence of disease progression at the end of at least 4 cycles of chemo- immunotherapy or 2 cycles of chemo-immunotherapy followed by 2 cycles of immunotherapy (CheckMate9LA regimen) and eligible for treatment with docetaxel. Any chemotherapy is allowed, including chemotherapy containing platinum salts. This criterion implies that patients with immunotherapy primary resistance are excluded; 4. Patients must have experienced progressive disease (PD), either during or within 3 months of discontinuing treatment with anti-PD-(L)1-based therapy, occurring after previous clear benefit (any complete –CR- or partial response -PR), or after previous stable disease (SD); 5. Performance status 0-1 (ECOG); 6. Patient compliance to trial procedures; 7. Age > or = 18 years; |
1. Pacientes masculinos y femeninos dispuestos y capaces de dar su consentimiento informado por escrito; 2. Diagnóstico histológico o citológico confirmado de CPCNP HLA-A2+ sin evidencia de mutaciones del EGFR o reordenamientos de ALK o ROS1; 3. Evidencia de progresión de la enfermedad al final de al menos 4 ciclos de quimioinmunoterapia o 2 ciclos de quimioinmunoterapia seguidos de 2 ciclos de inmunoterapia (régimen CheckMate9LA), y apto para el tratamiento con docetaxel. Se permite cualquier quimioterapia, incluida la que contiene sales de platino. Este criterio significa que se excluyen los pacientes con resistencia primaria a la inmunoterapia; 4. Los pacientes deben haber experimentado una progresión de la enfermedad (PE), durante o dentro de los 3 meses siguientes a la interrupción del tratamiento con anti-PD-(L)1, que se produzca después de un claro beneficio (respuesta completa -CR- o respuesta parcial -PR-), o después de una enfermedad estable (EE); 5. Estado de rendimiento 0-1 (ECOG); 6. El paciente respeta los procedimientos del estudio; 7. Edad> o = 18 años; |
|
E.4 | Principal exclusion criteria |
1. Patient positive for actionable EGFR mutations or ALK or ROS1 rearrangement; 2. No previous chemoimmunotherapy for metastatic disease or evidence of disease progression during the first 4 cycles of chemoimmunotherapy (primary resistance). Patients with adjuvant resistance (documented loco-regionally and/or systemic relapse of their disease occurring <6 months after the last dose of anti-PD-(L)1-based systemic adjuvant therapy) are excluded; 3. Patients with intervening systemic therapy following prior anti-PD-(L)1-based therapy; 4. Symptomatic brain metastases. Asymptomatic brain metastases are allowed if not requiring corticosteroids use at a dose >10mg daily prednisone (or equivalent); 5. Diagnosis of any other malignancy during the last 3 years, except for in situ carcinoma of cervix uteri and cutaneous squamous cell carcinoma or other local tumors considered cured; 6. Pregnancy or lactating; |
1. Paciente positivo para mutaciones del EGFR o reordenamiento ALK o ROS1. 2. Sin quimioinmunoterapia previa para la enfermedad metastásica o evidencia de progresión de la enfermedad durante los primeros 4 ciclos de quimioinmunoterapia (resistencia primaria). Se excluyen los pacientes con resistencia adyuvante (recidiva documentada de la enfermedad locorregional y/o sistémica que se produce < 6 meses después de la última dosis de tratamiento sistémico adyuvante basado en anti-PD-(L)1). 3. Pacientes en terapia sistémica intermedia después de una terapia previa con anti-PD- (L) 1. 4. Metástasis cerebrales sintomáticas. Las metástasis cerebrales asintomáticas están permitidas si no requieren corticosteroides. 5. Diagnóstico de cualquier otro tumor maligno en los últimos 3 años, excepto el carcinoma in situ de cuello uterino y el carcinoma escamocelular cutáneo u otros tumores locales considerados curados (por ejemplo, carcinoma de próstata localizado y presuntamente curado). 6. Embarazo o lactancia. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1-year Survival Rate |
Tasa de supervivencia a un año |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
• Overall Survival (OS) (1 and 2-year OS) • Progression-free survival (PFS) (1 and 2-year PFS) • Objective Response rate (ORR) • Safety Exploratory • Correlation of ORR, PFS and OS with tumor biomarkers |
• Supervivencia global (SG) (mediana, SG a 1 y 2 años) • Supervivencia sin progresión (SSP) (SSP a 1 y 2 años) • Tasa de respuesta objetiva (TRO) • Seguridad Exploratorio • Correlación entre TRO, SSP, SG y biomarcadores en sangre y tejido tumoral. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
1 and 2 years 1 and 2 years Every 8 weeks Every 3 weeks Exploratory: 48 months |
1 y 2 años 1 y 2 años Cada 8 semanas Cada 3 semanas Exploratorio: 48 meses |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 3 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 24 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Última visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 36 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial months | 48 |